MIR4728 (MicroRNA 4728)

A further study showed that quercetin upregulates the expression of p53 by regulating the lncRNA DDB2-AS1/miR-4728-5p pathway, thereby inducing ferroptosis in cisplatin-resistant NSCLC cells, thus overcoming cisplatin resistance. These findings demonstrate that quercetin induces ferroptosis through the DDB2-AS1/miR-4728-5p/p53 axis, thereby reversing cisplatin resistance in NSCLC, and highlighting its potential as an effective adjuvant in NSCLC chemotherapy.

The consistent enrichment of these miRNAs in exosomes underscores their potential as exploratory biomarkers for future liquid-biopsy-based applications. To our knowledge, this discovery-phase investigation is the first to associate this exosomal miRNA panel with TNBC and its stem-like subpopulations, providing a preliminary framework for subsequent mechanistic and translational validation.

Our findings highlight the exceptional diagnostic performance of the miRNA signature as a stratifying biomarker for distinguishing between AC and SCC subtypes in lung cancer. The developed molecular diagnostic model holds promise for providing a more accurate and comprehensive molecular characterization of NSCLC, thereby guiding personalized treatment decisions and improving clinical management and prognosis for patients.

Our study presents a comprehensive and systematic analysis of M7G-related miRNAs to construct a prognostic signature in BRCA. The signature demonstrated excellent prognostic validity, with the risk score as an independent prognostic factor. These results provide critical evidence for further investigation of M7G miRNAs and offer new insights for BRCA patients in the context of effective immunotherapy.

Our study comprehensively investigates the exo-miRNA profiles in MM patients. A novel prognostic signature wasconstructed to facilitate the risk stratification of MM patients with distinct outcomes. Multiple myeloma, Prognosis, liquid biopsy